Pharmacist-managed titration of urate-lowering therapy to streamline gout management

被引:8
作者
Huang, Irvin J. [1 ]
Liew, Jean W. [2 ]
Morcos, Meredith B. [3 ]
Zuo, Silu [4 ]
Crawfords, Carol [5 ]
Bays, Alison M. [2 ]
机构
[1] Univ Washington, Dept Med, Boise, ID USA
[2] Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA
[3] Virginia Mason Med Ctr, Rheumatol, Seattle, WA 98101 USA
[4] Univ Washington, Pharm, Seattle, WA 98195 USA
[5] Harborview Med Ctr, Pharm, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
Crystal arthropathies; Hyperuricemia; Gout; Patient compliance; US GENERAL-POPULATION; CARE; ADHERENCE; HYPERURICEMIA; PREVALENCE; GUIDELINES; HEALTH; TARGET; TREAT;
D O I
10.1007/s00296-019-04333-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines. Adherence to urate-lowering therapy (ULT) can be difficult for patients due to barriers, which include medication burden, financial hardship, and lack of medical literacy. Our aim was to create a pharmacist-managed referral for the titration of ULT to target serum uric acid (sUA) levels in a complex patient population. We utilized a clinical database to query patients seen at a rheumatology clinic over a 12-month period with an ICD-10 diagnosis for gout. The referral criteria were indications for ULT per the 2012 ACR guidelines. Rheumatology providers, consisting of attendings, fellows, and a physician assistant, were asked to refer the identified patients to the pharmacist-managed titration program. The intervention group consisted of 19 referred patients and the control group consisted of 28 non-referred patients. The baseline sUA (median (IQR)) at the time of referral was 8.8 (2) mg/dL for the intervention group and 7.6 (2.8) mg/dL for the control group (p = 0.2). At the end of the study period, the sUA was 6.1 (1.4) mg/dL for the intervention group and 6.8 (3.2) mg/dL for the control group (p = 0.08). At the end of the study period, 6 of 19 (32%) intervention group and 7 of 28 (25%) control group were at goal (p = 0.3). A newly instituted pharmacist-managed titration program was able to achieve lower average sUA levels in referred patients compared to demographically similar individuals who received standard gout management.
引用
收藏
页码:1637 / 1641
页数:5
相关论文
共 50 条
  • [1] Pharmacist-managed titration of urate-lowering therapy to streamline gout management
    Irvin J. Huang
    Jean W. Liew
    Meredith B. Morcos
    Silu Zuo
    Carol Crawford
    Alison M. Bays
    Rheumatology International, 2019, 39 : 1637 - 1641
  • [2] Treatment approaches and adherence to urate-lowering therapy for patients with gout
    Aung, Thanda
    Myung, Gihyun
    FitzGerald, John D.
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 795 - 800
  • [3] Urate-Lowering Therapy for Gout: Focus on Febuxostat
    Love, Bryan L.
    Barrons, Robert
    Veverka, Angie
    Snider, K. Matthew
    PHARMACOTHERAPY, 2010, 30 (06): : 594 - 608
  • [4] Urate-Lowering Therapy for the Management of Gout: Summary of 2 Cochrane Reviews
    Kydd, Alison S.
    Seth, Rakhi
    Buchbinder, Rachelle
    Falzon, Louise
    Edwards, Christopher J.
    van der Heijde, Desiree M.
    Bombardier, Claire
    JOURNAL OF RHEUMATOLOGY, 2014, 41 : 33 - 41
  • [5] Urate-lowering therapy for patients with gout on hemodialysis
    Alkilany, Reem
    Einstadter, Douglas
    Antonelli, Maria
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (07) : 769 - 774
  • [6] Combination urate-lowering therapy in the treatment of gout: What is the evidence?
    Perez-Ruiz, Fernando
    Dalbeth, Nicola
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (04) : 658 - 668
  • [7] Ultrasound in gout: A useful tool for following urate-lowering therapy
    Ottaviani, Sebastien
    Gill, Ghislaine
    Aubrun, Aurore
    Palazzo, Elisabeth
    Meyer, Olivier
    Dieude, Philippe
    JOINT BONE SPINE, 2015, 82 (01) : 42 - 44
  • [8] 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy
    Pascart, Tristan
    Latourte, Augustin
    Flipo, Rene-Marc
    Chales, Gerard
    Coblentz-Baumann, Laurence
    Cohen-Solal, Alain
    Ea, Hang-Korng
    Grichy, Jacques
    Letayernier, Emmanuel
    Liote, Frederic
    Ottaviani, Sebastien
    Sigwalt, Pierre
    Vandecandelaere, Guy
    Richette, Pascal
    Bardin, Thomas
    JOINT BONE SPINE, 2020, 87 (05) : 395 - 404
  • [9] Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
    Dalbeth, Nicola
    House, Meaghan E.
    Horne, Anne
    Petrie, Keith J.
    McQueen, Fiona M.
    Taylor, William J.
    BMC MUSCULOSKELETAL DISORDERS, 2012, 13
  • [10] A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout
    Phang, Kee Fong
    Santosa, Amelia
    Low, Bernadette P. L.
    Tan, Pamela S. H.
    Khong, Zhi Wei
    Lim, Anita Y. N.
    Teng, Gim Gee
    Tay, Sen Hee
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (09) : 1136 - 1144